rapidly progressing alzheimer patients mutation mean drug promise mirage dr. paul aisen runs alzheimer therapeutic research institute university southern california said discrepancy create potential bias trials patients confirmed amyloid brains outset case ban2401 impact apoe4 progression modest aisen wrote email not think accounts apparent slowing cognitive decline high dose arm sperling agreed not think arms different populations skewed data group received second highest dose drug larger share apoe4 carriers saw results similar not substantial high dose group similar pattern said partially mitigates concern biogen eisai promised dig data parse effect apoe4 patients responded ban2401 results likely will not ready months